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Abstract
Nanoscale coordination polymers (NCPs) have been demonstrated as an interesting platform for
drug delivery, as they possess many advantages over small-molecule chemotherapeutics, such as
high payloads, lower systemic toxicity, tunability, and enhanced tumor uptake. Existing
formulations for the delivery of methotrexate (MTX), an antifolate cancer drug, have very low
drug loadings. Herein, we report the incorporation of MTX as a building block in an NCP
formulation with exceptionally high drug loadings (up to 79.1 wt%) and the selective delivery of
the NCP to cancer cells. Encapsulation of the NCP in a functionalized lipid bilayer allows for
targeted delivery and controlled release to cancer cells. A phosphor can be doped into the NCPs
for monitoring particle uptake by optical imaging. The lipid-coated and anisamide-targeted NCPs
have superior in vitro efficacy against acute lymphoblastic leukemia cells when compared to free
drug.
Introduction
Coordination polymers, also known as metal-organic frameworks (MOFs), have recently
emerged as an interesting class of hybrid materials comprised of organic bridging ligands
coordinatively bound to metal-connecting points.1–2 The highly tunable nature of
coordination polymers has allowed the design of numerous promising materials for a
number of applications, including catalysis,3–8 nonlinear optics,9 light harvesting,10
selective gas adsorption,11–12 chemical sensing,13–16 and gas storage.17–22 When these
materials are scaled down to the nano-regime to afford nanoscale coordination polymers
(NCPs), they can be exploited for a number of biomedical applications.23–26 For example,
we and others have demonstrated the potential utility of NCPs in magnetic resonance
imaging,27–32 computed tomography,33 optical imaging,34–35 and biosensing.36 Whereas
Horcajada and coworkers demonstrated the delivery of chemotherapeutics in the pores of the
MIL family of NCPs,37 our group successfully delivered cisplatin prodrugs by either direct
incorporation of the prodrug into an NCP or by postsynthetic covalent attachment of a
prodrug to a pre-synthesized NCP.38–39 In this work, we are utilizing a different direct
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incorporation strategy to deliver organic antifolate chemotherapeutics possessing functional
groups that can bridge metal-connecting points in NCP formulations.40–41
Methotrexate (MTX) is a small molecule chemotherapeutic agent that works by inhibiting
dehydrofolate reductase, thereby preventing DNA synthesis. While MTX is toxic to many
cancer cells and is the first-line treatment for acute lymphoblastic leukemia (ALL), its
efficacy is compromised by an array of drawbacks, including poor pharmacokinetics, low
tolerated doses, and resistance.42 Large doses of MTX are required as a result of its non-
specific distribution and rapid renal clearance, which can lead to systemic toxicity.
Prolonged MTX treatment of ALL patients can result in numerous side effects such as
mucositis, hematological toxicity, and secondary cancer. Drug delivery with nanoparticulate
carriers can overcome many of the drawbacks of conventional chemotherapy, as
nanoparticles can carry a large payload and significantly improve tumor uptake by taking
advantage of the enhanced permeation and retention (EPR) effect.43 Drug encapsulation in
liposomes has, for example, led to enhanced efficacy due to improved pharmacokinetics.44
Tumor uptake of nanotherapeutics can be further improved by surface conjugation of
affinity molecules that bind to certain receptors overexpressed by cancer cells.43
Although several nanoparticle systems have been examined for MTX delivery, relatively
low drug loadings were achieved in these studies.45–50 We hypothesized that MTX can be
incorporated into NCPs as a bridging ligand since it contains two carboxylate groups which
can coordinate to metal connecting points. Very high loadings of MTX can be achieved in
such NCP formulations. Thus, we wish to report the synthesis and characterization of MTX-
based NCPs, their stabilization and cancer targeting with a lipid bilayer, and in vitro efficacy
against Jurkat ALL cells (Scheme 1). A carboxylic acid derivative of luminescent
Ru(bpy)32+ (bpy = 2,2’-bipyridine) was also incorporated into the NCPs to allow the
monitoring of MTX uptake by cancer cells via confocal microscopy.
Experimental Section
Synthesis of Zn-MTX NCP (1)
NCPs of 1 were synthesized by a high-temperature surfactant-assisted method. Two
microemulsions with W=15 were prepared by the addition of 270 µL of an aqueous solution
of MTX dimethylammonium salt (0.10 M, pH=10.6) and 270 µL of an aqueous solution of
Zn(NO3)2·6H2O (0.11 M) to separate 10 mL aliquots of a 0.1 M CTAB/0.5 M 1-hexanol/
isooctane mixture. The separate microemulsions were stirred vigorously for 10 min at room
temperature, then the two microemulsions were combined, and the resultant 20 mL
microemulsion with W=15 was transferred to a sealed microwave vessel. The reaction was
rapidly heated to 120 °C, and held at this temperature for 10 min with stirring. After cooling,
the nanoparticles were isolated by centrifugation at 13,000 rpm for 10 min. After the
removal of the supernatant, the particles were washed twice, using 10 mL of ethanol each
time. For each wash, the particles were redispersed by sonication and then recovered by
centrifugation at 13,000 rpm for 10 min. Yield: 11.8 mg (84.2%).
Synthesis of Zr-MTX NCP (2)
ZrCl4 (6.99 mg, 0.03 mmol) was dissolved in 6 mL N,N-dimethylformamide (DMF),
followed by 13.67 mg (0.03 mmol) methotrexate. The clear yellow solution was placed in a
sealed microwave vessel and heated at 60 °C for 5 minutes (300 W, 200 psi) without
stirring. The product was isolated from the resulting yellow dispersion by centrifugation at
13,000 rpm for 15 min, washed by sonication and centrifugation, with H2O then EtOH, and
dispersed in EtOH. Yield: 8.88 mg (54.4%).
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Synthesis of Gd-MTX NCP (3a)
Both Gd(NO3)3·6H2O (13.54 mg, 0.0300 mmol) and MTX (13.63 mg, 0.0300 mmol) were
dissolved in 6 mL DMF and the solution was heated in a sealed microwave vessel at 80 °C
for 5 min without stirring. The product was isolated from the resulting yellow dispersion by
centrifugation at 13,000 rpm for 15 min, washed by sonication and centrifugation, with
DMF then EtOH, and dispersed in EtOH. Yield: 15.6 mg (85%).
Synthesis of Gd-folate NCP (4a)
22.5 mg (0.0498 mmol) Gd(NO3)3·6H2O was dissolved in 3 mL DMF, and 22.2 mg (0.0503
mmol) folic acid was dissolved in 7 mL DMF by heating. The procedure was similar to that
of 3a. Yield: 7.5 mg (25.2%).
Synthesis of [Ru(5,5’-CO2-bpy)(bpy)2]-doped analogs of 3a–c and 4a–c
10 mol% [Ru(5,5’-CO2-bpy)(bpy)2]-doped 3a was synthesized by the same procedure as 3a,
but with the addition of 2.02 mg (0.00308 mmol, 10 mol%) [Ru(5,5’-CO2Hbpy)( bpy)2]
(PF6)2 to the DMF solution. Particles were isolated in a yield of 20.9 mg (72%). 10 mol%
[Ru(5,5’-CO2-bpy)(bpy)2]-doped 4a was synthesized by the same procedure as 4a, but with
the addition of 3.3 mg (0.0050 mmol, 10 mol%) Ru(bpy)2(bby-CO2H) to the DMF solution.
Particles were isolated in a yield of 9.45 mg (29%). Synthesis of lipid-coated versions of
doped 3a and 4a were carried out by the same methods for 3b, 3c, 4b, and 4c.
Synthesis of Lipid-Coated NCPs
a). Synthesis of DSTAP/DOPE-coated 3a—Particle dispersions of 3a and 1:1 (by mol)
DSTAP/DOPE liposomes in 1 mM aq. KCl were heated to 70 °C and mixed together. The
dispersion was vortexed and was allowed to sit at room temperature for 30 minutes. Empty
liposomes were removed by centrifugation at 6,000 rpm for 10 minutes, and the resulting
particles of 3b were redispersed in 1 mM aq. KCl by sonication.
b). Synthesis of DSTAP/DOPE-AA-coated 3a—These lipid-coated particles were
produced by the same technique as 3b, but using 1:1 (by mol) DSTAP/DOPE liposomes,
incorporating 10 mol% DOPE-AA.
Cytotoxicity assay of 3a, 3b, and 3c against Jurkat cells
Confluent Jurkat cells were counted from the culture flask by hemocytometer. Cells were
plated in 6-well plates at a cell density of 5 × 104 cells/well in 1.5 mL RPMI-1640 complete
growth medium. The cells were incubated at 37 °C and 5% CO2 overnight. MTX and
particle dispersions of 3a, 3b, and 3c (16 µM) in RPMI-1640 media and additional media
were added to wells, resulting in MTX concentrations (µM) of 0, 0.25, 0.5, 1, 2, and 4. Cells
were incubated (37 °C, 5% CO2) with free MTX or particle for 48 h or for 72 h. Viability
was determined by the trypan blue exclusion assay.
Viability control assays with Jurkat cells
This assay was conducted to show that MTX is the only contributor to cytotoxicity and that
Gd3+ has no bearing on the cytotoxicity. Gd(NO3)3, 4a, 4b, and 4c were tested against
Jurkat acute lymphoblastic leukemia cells. Confluent Jurkat cells were counted from the
culture flask by hemocytometer. Cells were plated in 6-well plates at a cell density of 5 ×
104 cells/well in 1.5 mL RPMI-1640 complete growth medium. The cells were incubated at
37 °C and 5% CO2 overnight. Free Gd3+ and particle dispersions (200 µM) in RPMI-1640
media and additional media were added to wells, resulting in folate concentrations (µM) of
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0, 0.5, 1, 2.5, 5, and 10. Cells were incubated (37 °C, 5% CO2) with free Gd3+ or particles
for 48 h. Viability was determined by the trypan blue exclusion assay.
Confocal microscopy of [Ru(5,5’-CO2-bpy)(bpy)2]-doped analogs of 3a–c and 4a–c
Wells in 6-well plates were seeded with 500,000 cells and 2 mL total of RPMI-1640 media
(10% FBS, 2% penicillin-streptomycin). The plates were incubated for 24 h at 37 °C and 5%
CO2. Particle dispersions were prepared in RPMI-1640 medium, and aliquots of particle
dispersions/additional media were added to the wells, resulting in a concentration of 0.04
mg/well for each particle. The cells were incubated with particles for 1 h, and cell
suspensions were centrifuged. Cell pellets were re-suspended in PBS, 15 µL Annexin V
FITC conjugate was added, and the cells were allowed to sit at room temperature for 10 min.
The cells were centrifuged and redispersed in 20µL of media. The entire cell suspension was
placed on glass coverslips, adhered on glass slides with antifade mounting medium, and
imaged at the UNCCH Microscope and Imaging Facility.
Results and Discussion
Synthesis and Characterization of MTX-Containing NCPs
Three new NCPs were synthesized using MTX as the bridging ligand and either Zn2+, Zr4+,
or Gd3+ ions as the metal-connecting points. The properties of the NCPs, especially stability,
can be tuned by the choice of metal ion. Zn2+ was originally chosen as the metal linker for a
MTX-containing NCP due to its biocompatibility. Zn-MTX (1) was synthesized in 84%
yield by first preparing a microemulsion of 0.1 M CTAB (CTAB =
cetyltrimethylammonium bromide) and 0.5 M 1-hexanol in isooctane with a water-to-
surfactant ratio (W) of 15, containing [CH3NH3]2(MTX) and Zn(NO3)2. Surfactant-assisted
synthesis was carried out by microwave heating of the microemulsion in a sealed vessel at
120 ° C for 10 min, with stirring. The particles were isolated by centrifugation and washed
with ethanol. Both scanning electron microscopy (SEM) and transmission electron
microscopy (TEM) showed that particles of 1 are spherical with a diameter between 40 and
100 nm (Fig 1a). Dynamic light scattering (DLS) in ethanol gives a number average size of
161 nm, slightly larger than the size observed by microscopy due to slight aggregation in
this medium. These particles were shown by thermogravimetric analysis (TGA) (Fig. 2a) to
contain 79.1 wt% MTX based on the organic weight loss. Powder X-ray diffraction (PXRD)
reveals the amorphous structure of these particles by the lack of diffraction peaks (Fig. S3).
Attempts were made to coat 1 with a biocompatible shell (either silica or a lipid bilayer), but
the particles were not stable under coating conditions. Coating 1 with a layer of silica by
hydrolysis and condensation of tetraethylorthosilicate (TEOS) was unsuccessful because the
ammonium hydroxide catalyst causes severe erosion of the particles. Lipid-coating of 1 also
failed due to particle agglomeration in aqueous media. Additionally, the zeta potential of the
particles is close to neutral (−1.9 mV), precluding efficient electrostatic interactions with
positively-charged liposomes.
We hypothesized that more robust NCPs could be synthesized using Zr4+ in place of Zn2+
metal-connecting points, due to the strength of the Zr-carboxylate bond.51 Zr-MTX (2) was
synthesized in 54% yield by microwave heating of a solution of MTX and ZrCl4 in N,N-
dimethylformamide (DMF) at 60 °C for 5 min in a sealed vessel. The resulting spherical
particles had a diameter of 70 to 180 nm by both SEM and TEM (Fig. 1b), and 88.4 nm by
DLS (Fig. 2b). Particles of 2 had a high MTX loading of 78.2% by TGA. As-synthesized 2
had a zeta potential (1 mM aq. KCl) of −27.2 mV. This negative zeta potential, along with
stability in water, allows for coating of these particles with a cationic lipid bilayer to provide
biocompatibility and stabilization in physiologically relevant media.52–54 2 was coated with
different liposomal formulations, such as 4:48:48 (by mol) DOTAP/DOPE/cholesterol
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(DOTAP = dioleoyl trimethylammonium propane and DOPE = dioleoyl L-α-
phosphatidylethanolamine), 1:1 (by mol) DOTAP/cholesterol, DOTAP, DSTAP (DSTAP =
1,2-stearoyl-3-trimethylammonium propane), and 1:1 (by mol) DSTAP/DOPE. Different
liposomal formulations were made by drying a chloroform solution of lipids to create a film
that was then hydrated with 1 mM aq. KCl. The resulting liposomes were extruded through
polycarbonate membranes several times to obtain unilamellar vesicles with sizes ranging
from 25–160 nm, depending on the formulation. Zeta potentials ranged from 50 to 60 mV.
Dispersions of liposomes and 2 were mixed together, and empty liposomes were removed
by centrifugation at low speed. Coating occurs by rearrangement of the cationic liposomes
onto the anionic surface of the particles, resulting in encapsulation of 2 in a lipid bilayer.
Lipid coating of 2 was verified by an increase in the zeta potential from −27.2 mV to 25–50
mV. However, lipid coating failed to provide any significant stabilization over the as-
synthesized particles in phosphate buffered saline (PBS) or simulated body fluid (SBF). The
half-life for both coated and bare particles was approximately 2.5 h in PBS and 0.5 h in SBF
at 37 °C and pH = 7.4 (Fig. S6, S7). We speculate that lipid coating failed to stabilize 2
owing to the strong driving force in forming Zr3(PO4)4 in the presence of phosphate ions.
For comparison, Zr3(PO4)4 has a Ksp value of 10−134 while Zn3(PO4)2 has a Ksp value of
10−34.
Considering our inability to stabilize 1 and 2, we rationalized that a formulation containing a
metal less labile than zinc, but with a phosphate Ksp much greater than that of Zr3(PO4)4,
would prove easier to stabilize by lipid coating. Trivalent lanthanide ions have much greater
Ksp values (10−23 for Gd(PO4) and should provide a good balance between particle stability
and lipid stabilization toward lanthanide phosphate formation. Gd-MTX NCP, 3a, was
synthesized in 85% yield by microwave heating of a solution of MTX and Gd(NO3)3 in
DMF at 80 ° C for 5 min in a sealed vessel. The as-synthesized particles of 3a were spheres
of 70 to 200 nm by SEM and TEM (Fig. 1c) and 77.7 nm by DLS (Fig. 2b). By TGA, these
particles contain 71.6 wt% MTX (Fig. 2a). With a zeta potential (1 mM aq. KCl) of −10.0
mV, 3a can be coated with a cationic liposome in order to further stabilize these particles.
Stabilization of Gd-MTX NCP With A Lipid Bilayer
The half-life of 3a is only 2 h in 8 mM PBS at 37 °C, and needs to be prolonged for many
biological applications (Fig. 2c). Stabilization with a lipid bilayer was pursued, due to the
biocompatibility and known biological stability of this coating.52–54 Thus, 3a was coated
with a 1:1 (by mol) DSTAP/DOPE liposomal formulation. These liposomes were made as
previously discussed and had an average size of 94.3 nm and a zeta potential of 59.5 mV by
DLS. The liposomes were mixed with a particle dispersion of 3a in 1 mM aq. KCl at a 10:1
particle:lipid weight ratio to obtain 3a encapsulated in a lipid bilayer (3b). Complete
coverage is indicated by an increase in the zeta potential to 32.6 mV, and a size similar to
the as-synthesized particles. Complete coverage of individual particles with a lipid bilayer
was confirmed by TEM (Fig. 1f). 3b, when stained with 5% aq. uranyl acetate, exhibited
dark rings around each particle due to strong binding of uranyl ions with the phosphates of
DOPE in the lipid bilayer.55 The lipid bilayer stabilized the particles against dissolution, as
evidenced by a release profile in 8 mM PBS (37 °C, pH = 7.4). MTX release was monitored
by UV-Vis spectroscopy as the particles were dialyzed. The half-life of 3b was 23 h,
compared to t1/2 = 2 h for 3a, with 100% release at 192 h (Fig. 2c). It is worth noting that
lipid-coated NCPs are individual, lipid-stabilized, solid particles and are different from
conventional liposomes.56
In order to improve delivery of nanoparticles in vitro, particles can be modified with affinity
molecules to target receptors which are overexpressed on the surface of tumor cells. For
example, sigma receptors are overexpressed on a number of different human cancer cell
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lines, including lung, colorectal, breast, and others.57 These sigma receptors can be targeted
by small benzamides, such as anisamide (AA).58–60 For this work, we were able to
conjugate AA to the primary amine of DOPE and integrate approximately 10 mol% of this
lipid into the liposomal formulation before lipid coating of 3a, resulting in AA-
functionalized particles (3c). The particle size of 3c is similar to that of the as-synthesized
particles, and the zeta potentials are positive, indicating coverage by the cationic liposome.
Synthesis and Characterization of Gd-Folate NCP Control Vehicles
As a control, a non-cytotoxic analog of 3a was synthesized by substituting folic acid, a
naturally-occurring nutrient, for MTX to give a Gd-folate NCP (4a). Folic acid has a
structure similar to MTX, with two carboxylic acid groups which can coordinate to metal
ions. These particles were synthesized in DMF with microwave heating in a similar fashion
to 3a. The resulting particles were 200–300 nm by SEM, and 262 nm by DLS. These
particles have a zeta potential of −11.8 mV (1 mM aq. KCl), and can be coated with 1:1 (by
mol) DSTAP/DOPE liposomes (4b) and functionalized with AA (4c) by the methods
described for 3a. Control vehicles 4a–c do not contain any anticancer agent and were
utilized in cytotoxicity and confocal microscopy experiments as analogs of 3a–c.
Enhanced in vitro Efficacy of Lipid-Coated Gd-MTX NCPs
3a, 3b, and 3c all showed enhanced efficacy compared to free MTX in vitro against Jurkat
human ALL cells. Jurkat cells are known to overexpress sigma receptors,61 and can
therefore be subjected to AA-targeting. Cells were incubated with MTX or NCPs for 72 h,
and then viability was determined by the trypan blue exclusion assay. 3a was slightly less
cytotoxic than free MTX (IC50 = 34.7±2.5 nM), with an IC50 of 54.7±2.3 nM. Improved
efficacy of 3a over free MTX is not expected due to the rapid degradation of these particles
in biological media. The lipid coating on 3b significantly improved efficacy with an IC50
value of 28.3±0.6 nM; this enhancement is contributed to the affinity of cationic lipid
bilayers for cell membranes. AA targeting proved successful, with 3c having a slightly
lower, statistically significant, IC50 (23.7±1.5 nM) than the lipid-coated formulation (Fig.
2d). Free Gd3+ salt and 4a–c were also tested (Fig. S16), and did not exhibit any cytotoxic
effect in the same concentration range, proving that MTX, not Gd3+, is responsible for
cytotoxicity of 3a–c. 1 and 2 were also tested against human cancer cell lines (Fig. S13,
S14), and no enhancement in efficacy over free MTX was observed, presumably due to their
rapid degradation in biological media to release free MTX.
1. Optical Imaging of Gd-MTX NCPs With Jurkat Human ALL Cells
3a and 4a were doped with approximately 10 mol% of a carboxylic acid derivative of the
phosphor Ru(bpy)32+ so that this platform can be used for optical imaging. Additionally, this
doping strategy allows for further verification of successful lipid coating when the lipid is
functionalized with FITC (fluoroscein isothiocyanate) (Fig. S9). The doped particles were
synthesized in DMF by the same method as 3a and 4a but with the addition of 10 mol% of
the Ru(bpy)32+ derivative. The doped particles had similar sizes, ligand loadings, and zeta
potentials compared to their undoped counterparts, allowing phosphorescent versions of 3b,
3c, 4b, and 4c to be made from doped 3a and 4a. Laser scanning confocal fluorescence
microscopy was performed on Jurkat cells incubated with NCPs to assess the imaging and
targeting efficiency of the NCPs. The cells were also stained with Annexin V FITC
conjugate to assay for early apoptosis. As displayed in Fig. 3, co-localized fluorescence
signal is observed in the cells from the Ru(bpy)32+-doped particles (red) and the apoptosis
stain (green) for 3b. Significantly stronger red and green fluorescence signals are seen for
3c, due to increased cell uptake of the targeted particles, and hence increased cytotoxicity.
No red or green fluorescence was observed for 3a, as these particles disintegrate quickly,
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and do not have a mechanism to permeate the cell membrane during the 1 h incubation time
for the experiment. Fluorescence from Ru(bpy)32+ was observed for the cells incubated with
4b and 4c, similar to 3b and 3c. However, as expected, no apoptosis (green fluorescence)
was observed for 4a–c (Fig. S18).
Conclusions
We have successfully formulated novel NCPs containing up to 79.1 wt% methotrexate. Gd-
MTX NCPs were stabilized by a DSTAP/DOPE lipid bilayer. A DOPE-AA conjugate was
incorporated into the lipid bilayer and used to target sigma receptors overexpressed on
leukemia cancer cells. The NCPs were doped with 10 mol% of a carboxylated Ru(bpy)32+
derivative, which serves as an optical imaging agent, as evidenced by confocal microscopy
of Jurkat human acute lymphoblastic leukemia cells. Finally, lipid-coated and targeted NCPs
were shown to have superior efficacy compared to the as-synthesized particles or free drug
in in vitro cytotoxicity assays with Jurkat cells. We believe that this NCP formulation
strategy is general and can be applied to deliver many other organic anticancer drugs.
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TEM images of 1 (a), 2 (b), 3a (c, e), and 3b (d, f). The samples shown in e and f have been
stained with uranyl acetate to highlight the lipid bilayer coating on 3b. The scale bars
represent 400 nm for a–d, and 100 nm for e–f.
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a) TGA curves for 1, 2, and 3a. b) Particle size distributions for 3a, 3b, and 3c obtained by
DLS. c) Release profiles in PBS for free MTX, 3a, and 3b obtained by measuring the release
of MTX by UV-Vis spectroscopy. d) IC50 values for free MTX, 3a, 3b, and 3c obtained
from in vitro cytotoxicity assays with a range of MTX concentrations against Jurkat human
ALL cells. Error bars represent one standard deviation.
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a–c) Differential interference contrast (DIC) images and d–i) fluorescence images of Jurkat
cells incubated with 3a (d,g), 3b (e,h), and 3c (f,i). Red fluorescence (d–f) is from the
Ru(bpy)32+-doped particles and green fluorescence (g–i) is from the Annexin V FITC
conjugate early apoptosis stain. Scale bars represent 25 µm.
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Synthesis of NCPs and functionalization of MTX-containing NCPs with a lipid bilayer and
targeting moiety.
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Table 1
DLS data[a] and MTX loadings[b] for MTX-based NCPs.
No. avg Zeta potential
Sample size (nm) PDI (mV) wt % MTX
1 161[c] 0.20[c] −1.9 79.1
2 88.4 0.18 −27.2 78.2
3a 77.7 0.04 −10.0 71.6
3b 64.6 0.24 32.6 ~69.2[d]
3c 76.8 0.15 25.3 ~69.0[d]
[a]
Obtained in 1 mM aq. KCl unless otherwise noted.
[b]




Estimated based on lipid coating content.
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